Literature DB >> 25092091

Induction of chemokine (C-C motif) ligand 2 by sphingosine-1-phosphate signaling in neuroblastoma.

Mei-Hong Li1, Miriam Harel2, Timothy Hla3, Fernando Ferrer4.   

Abstract

BACKGROUND/
PURPOSE: Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Preliminary data derived from a human angiogenesis array in NB showed that the bioactive lipid sphingosine-1-phosphate (S1P) induced the secretion of several angiogenesis-related proteins including the important inflammatory factor chemokine (C-C motif) ligand 2 (CCL2). In the present study, we investigated the mechanism of S1P-induced CCL2 expression in NB.
METHODS: Quantitative real-time PCR and CCL2 ELISA were conducted to detect the mRNA expression and protein secretion of CCL2 in NB cells. Gain and loss of function studies were performed by using specific S1PR antagonists, adenoviral transduction and siRNA transfection. Macrophage F4/80 receptor in NB xenografts was detected by quantitative real-time PCR and immunohistochemistry staining.
RESULTS: S1P induced CCL2 mRNA expression and protein secretion in a time- and concentration-dependent manner in NB cells. Blockade of S1P2 signaling using the selective S1P2 antagonist JTE-013 inhibited S1P-induced CCL2 expression. Overexpression of S1P2 by adenoviral transduction increased CCL2 secretion while knockdown of S1P2 by siRNA transfection decreased S1P-induced CCL2 secretion in NB cells. Macrophage infiltration, as detected by F4/80 staining, was significantly decreased in JTE-013-treated NB xenografts.
CONCLUSIONS: Taken together, our data for the first time demonstrate that S1P induced the macrophage-recruiting factor CCL2 expression in NB cells via S1P2, providing new insights into the complicated functions of S1P2 in cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemokine (C-C motif) ligand 2; Neuroblastoma; Sphingosine 1-phosphate; Sphingosine 1-phosphate receptor 2; Tumor-associated macrophage

Mesh:

Substances:

Year:  2014        PMID: 25092091      PMCID: PMC4122984          DOI: 10.1016/j.jpedsurg.2014.04.001

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  35 in total

Review 1.  Structural and functional characteristics of S1P receptors.

Authors:  Teresa Sanchez; Timothy Hla
Journal:  J Cell Biochem       Date:  2004-08-01       Impact factor: 4.429

Review 2.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

Authors:  Kenneth LaMontagne; Amanda Littlewood-Evans; Christian Schnell; Terence O'Reilly; Lorenza Wyder; Teresa Sanchez; Beatrice Probst; Jeannene Butler; Alexander Wood; Gene Liau; Eric Billy; Andreas Theuer; Timothy Hla; Jeanette Wood
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 4.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Authors:  Jian Zhang; Yi Lu; Kenneth J Pienta
Journal:  J Natl Cancer Inst       Date:  2010-03-16       Impact factor: 13.506

5.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.

Authors:  Bin-Zhi Qian; Jiufeng Li; Hui Zhang; Takanori Kitamura; Jinghang Zhang; Liam R Campion; Elizabeth A Kaiser; Linda A Snyder; Jeffrey W Pollard
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

6.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.

Authors:  Kevin J French; Yan Zhuang; Lynn W Maines; Peng Gao; Wenxue Wang; Vladimir Beljanski; John J Upson; Cecelia L Green; Staci N Keller; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2010-01-08       Impact factor: 4.030

8.  Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells.

Authors:  S Huang; R K Singh; K Xie; M Gutman; K K Berry; C D Bucana; I J Fidler; M Bar-Eli
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

Review 9.  Neuroblastoma: biology, prognosis, and treatment.

Authors:  Julie R Park; Angelika Eggert; Huib Caron
Journal:  Pediatr Clin North Am       Date:  2008-02       Impact factor: 3.278

10.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  4 in total

1.  The Granuloma Response Controlling Cryptococcosis in Mice Depends on the Sphingosine Kinase 1-Sphingosine 1-Phosphate Pathway.

Authors:  Amir M Farnoud; Arielle M Bryan; Talar Kechichian; Chiara Luberto; Maurizio Del Poeta
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

2.  Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma.

Authors:  Mei-Hong Li; Rolf Swenson; Miriam Harel; Sampa Jana; Erik Stolarzewicz; Timothy Hla; Linda H Shapiro; Fernando Ferrer
Journal:  J Pharmacol Exp Ther       Date:  2015-06-23       Impact factor: 4.030

3.  Sphingosine-1-phosphate receptor 3 is implicated in BBB injury via the CCL2-CCR2 axis following acute intracerebral hemorrhage.

Authors:  Dingkang Xu; Qiang Gao; Fang Wang; Qianrui Peng; Guoqing Wang; Qingjie Wei; Shixiong Lei; Shengqi Zhao; Longxiao Zhang; Fuyou Guo
Journal:  CNS Neurosci Ther       Date:  2021-02-28       Impact factor: 5.243

Review 4.  "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.

Authors:  Kevin X Liu; Shweta Joshi
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.